Matyas joined Creoptix in 2012 coming from Nextech Invest, a Zurich based Venture Fund. Before, Matyas was with The Genetics Company, a Swiss Biotech Start-up. There he held positions in research and business development before he finally became CEO, eventually selling the core assets to Millipore (US). Matyas obtained his masters degree in biology from the Biocentre of the University of Basel and his PhD in Molecular Biology and Genetics from the University of Zurich. He furthermore holds an Executive MBA from the University of St. Gallen.